Larimar Therapeutics Inc
LRMR3.855USD
-0.145-3.63%
Market hours （ET）Quotes delayed by 15 min
329.95MMarket Cap
LossP/E TTM
More Details of Larimar Therapeutics Inc Company
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Larimar Therapeutics Inc Info
Ticker SymbolLRMR
Company nameLarimar Therapeutics Inc
IPO dateJun 19, 2014
CEOBen-Maimon (Carole S)
Number of employees65
Security typeOrdinary Share
Fiscal year-endJun 19
AddressThree Bala Plaza East. Suite 506
CityBALA CYNWYD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19004
Phone18445119056
Websitehttps://larimartx.com/
Ticker SymbolLRMR
IPO dateJun 19, 2014
CEOBen-Maimon (Carole S)
Company Executives of Larimar Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Edward Hamilton
Mr. Thomas Edward Hamilton
Independent Director
Independent Director
590.81K
-18.42%
Dr. Carole S. Ben-Maimon, M.D.
Dr. Carole S. Ben-Maimon, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
180.86K
-11.38%
Mr. Michael (Mike) Celano
Mr. Michael (Mike) Celano
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
82.56K
-8.20%
Dr. Russell G. (Rusty) Clayton, Sr.
Dr. Russell G. (Rusty) Clayton, Sr.
Chief Medical Officer
Chief Medical Officer
45.81K
+103.58%
Dr. Gopi Shankar, Ph.D.
Dr. Gopi Shankar, Ph.D.
Chief Development Officer
Chief Development Officer
10.63K
-62.46%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Director
Independent Director
2.00K
--
Mr. Joseph (Joe) Truitt
Mr. Joseph (Joe) Truitt
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Jeffrey W. Sherman, M.D.
Dr. Jeffrey W. Sherman, M.D.
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas Edward Hamilton
Mr. Thomas Edward Hamilton
Independent Director
Independent Director
590.81K
-18.42%
Dr. Carole S. Ben-Maimon, M.D.
Dr. Carole S. Ben-Maimon, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
180.86K
-11.38%
Mr. Michael (Mike) Celano
Mr. Michael (Mike) Celano
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
82.56K
-8.20%
Dr. Russell G. (Rusty) Clayton, Sr.
Dr. Russell G. (Rusty) Clayton, Sr.
Chief Medical Officer
Chief Medical Officer
45.81K
+103.58%
Dr. Gopi Shankar, Ph.D.
Dr. Gopi Shankar, Ph.D.
Chief Development Officer
Chief Development Officer
10.63K
-62.46%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Director
Independent Director
2.00K
--
Revenue Breakdown
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States (Country)
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Deerfield Management Company, L.P.
36.84%
RA Capital Management, LP
7.28%
Blue Owl Capital Holdings LP
7.04%
Millennium Management LLC
5.89%
Opaleye Management Inc.
4.48%
Other
38.47%
Shareholders
Shareholders
Proportion
Deerfield Management Company, L.P.
36.84%
RA Capital Management, LP
7.28%
Blue Owl Capital Holdings LP
7.04%
Millennium Management LLC
5.89%
Opaleye Management Inc.
4.48%
Other
38.47%
Shareholder Types
Shareholders
Proportion
Hedge Fund
64.78%
Investment Advisor
17.83%
Investment Advisor/Hedge Fund
9.19%
Venture Capital
7.34%
Research Firm
2.90%
Individual Investor
1.10%
Private Equity
0.94%
Family Office
0.08%
Bank and Trust
0.07%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
247
74.45M
86.98%
+1.55M
2025Q2
237
70.20M
94.16%
-3.03M
2025Q1
241
65.66M
102.55%
-8.64M
2024Q4
237
68.11M
106.77%
-7.20M
2024Q3
225
68.88M
107.96%
-7.04M
2024Q2
207
69.87M
109.52%
-2.95M
2024Q1
185
68.09M
106.93%
+8.87M
2023Q4
161
43.68M
97.08%
-3.08M
2023Q3
157
39.54M
87.67%
-8.23M
2023Q2
151
39.82M
92.04%
-2.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Deerfield Management Company, L.P.
30.61M
35.76%
+9.38M
+44.16%
Jul 31, 2025
RA Capital Management, LP
6.05M
7.06%
--
--
Jun 30, 2025
Blue Owl Capital Holdings LP
4.93M
5.76%
+150.00K
+3.14%
Jun 30, 2025
Millennium Management LLC
3.66M
4.27%
+2.98M
+443.11%
Jun 30, 2025
Opaleye Management Inc.
4.11M
4.8%
--
--
Aug 29, 2025
The Vanguard Group, Inc.
2.14M
2.5%
-75.78K
-3.42%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.75M
3.21%
-90.21K
-3.18%
Jun 30, 2025
Alyeska Investment Group, L.P.
2.08M
2.43%
+633.41K
+43.91%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
0.29%
iShares Micro-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
View more
iShares Neuroscience and Healthcare ETF
Proportion0.29%
iShares Micro-Cap ETF
Proportion0.04%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.02%
Avantis US Small Cap Equity ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 Value ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 28, 2020
Merger
12→1
May 28, 2020
Merger
12→1
May 28, 2020
Merger
12→1
May 28, 2020
Merger
12→1
Date
Type
Ratio
May 28, 2020
Merger
12→1
May 28, 2020
Merger
12→1
May 28, 2020
Merger
12→1
May 28, 2020
Merger
12→1
FAQs
Who are the top five shareholders of Larimar Therapeutics Inc?
The top five shareholders of Larimar Therapeutics Inc are:
Deerfield Management Company, L.P. holds 30.61M shares, accounting for 35.76% of the total shares.
RA Capital Management, LP holds 6.05M shares, accounting for 7.06% of the total shares.
Blue Owl Capital Holdings LP holds 4.93M shares, accounting for 5.76% of the total shares.
Millennium Management LLC holds 3.66M shares, accounting for 4.27% of the total shares.
Opaleye Management Inc. holds 4.11M shares, accounting for 4.80% of the total shares.
Deerfield Management Company, L.P. holds 30.61M shares, accounting for 35.76% of the total shares.
RA Capital Management, LP holds 6.05M shares, accounting for 7.06% of the total shares.
Blue Owl Capital Holdings LP holds 4.93M shares, accounting for 5.76% of the total shares.
Millennium Management LLC holds 3.66M shares, accounting for 4.27% of the total shares.
Opaleye Management Inc. holds 4.11M shares, accounting for 4.80% of the total shares.
What are the top three shareholder types of Larimar Therapeutics Inc?
The top three shareholder types of Larimar Therapeutics Inc are:
Deerfield Management Company, L.P.
RA Capital Management, LP
Blue Owl Capital Holdings LP
Deerfield Management Company, L.P.
RA Capital Management, LP
Blue Owl Capital Holdings LP
How many institutions hold shares of Larimar Therapeutics Inc (LRMR)?
As of 2025Q3, 247 institutions hold shares of Larimar Therapeutics Inc, with a combined market value of approximately 74.45M, accounting for 86.98% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -7.18%.
What is the biggest source of revenue for Larimar Therapeutics Inc?
In FY2019, the -- business generated the highest revenue for Larimar Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
